title: The alpha 2-adrenergic receptor antagonist yohimbine inhibits epinephrine-induced platelet aggregation in healthy subjects.
abstract: Onset of sudden death, myocardial infarction, and stroke occurs more likely in the morning hours. Similarly, a morning increase in epinephrine-induced platelet aggregation was observed accompanied by an increase in plasma catecholamines. Inhibition of the morning increase in platelet aggregation would be of therapeutic benefit. In this study the effect of the selective alpha 2-adrenergic receptor antagonist yohimbine on platelet aggregation was evaluated in healthy subjects. Yohimbine administered orally selectively antagonized epinephrine but not collagen, arachidonic acid, or adenosine diphosphate-induced ex vivo platelet aggregation. The lowest dose of yohimbine that significantly inhibited epinephrine-induced platelet aggregation was 8 mg. The inhibitory effect of yohimbine on platelet aggregation lasted 10 hours with the 12 mg dose. At the doses studied (4, 8, and 12 mg), yohimbine did not modify blood pressure, standing heart rate, or plasma catecholamine or glucose concentrations. Twelve milligrams of yohimbine moderately but significantly accelerated supine heart rate (mean maximal increase, 7 +/- 3 beats/min). Further clinical studies are needed to evaluate whether bedtime administration of 12 mg yohimbine may block the morning increase in epinephrine-induced platelet aggregation.
authors.affiliation: Department of Clinical Pharmacology, Hôpital Pitié-Salpêtrière, Paris, France.
authors.forename: I
authors.initials: I
authors.lastname: Berlin
authors.forename: B
authors.initials: B
authors.lastname: Crespo-Laumonnier
authors.forename: A
authors.initials: A
authors.lastname: Cournot
authors.forename: C
authors.initials: C
authors.lastname: Landault
authors.forename: F
authors.initials: F
authors.lastname: Aubin
authors.forename: J C
authors.initials: JC
authors.lastname: Legrand
authors.forename: A J
authors.initials: AJ
authors.lastname: Puech
mesh_terms: D000284:Administration, Oral; D000328:Adult; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology; D003094:Collagen / Q000037:antagonists & inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004837:Epinephrine / Q000037:antagonists & inhibitors* / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011897:Random Allocation; D015016:Yohimbine / Q000494:pharmacology*
chemical_list: D001095:Arachidonic Acids; D010975:Platelet Aggregation Inhibitors; D015016:Yohimbine; D003094:Collagen; D009638:Norepinephrine; D004837:Epinephrine